Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Author(s): Chiara Rocchi*, Lucrezia Lombardi, Serena Broggi, Maura Chiara Danni, Simona Lattanzi, Giovanna Viticchi, Lorenzo Falsetti, Marco Bartolini, Mauro Silvestrini and Laura Buratti

DOI: 10.2174/1871527321666220513121138

DownloadDownload PDF Flyer Cite As
Impact of Dimethylfumarate on Sleep in Multiple Sclerosis Patients: An Actigraphic Study

Page: [1102 - 1108] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: Sleep disorders in multiple sclerosis (MS) patients are common. Dimethylfumarate is an oral disease-modifying drug (DMT), whose impact on sleep is unknown.

Objective: The aim of this study was to characterize actigraphic patterns in MS patients treated with dimethylfumarate.

Methods: Twenty relapsing-remitting MS patients with low to a mild disability, aged 20-50y, treated with dimethylfumarate for more than 6 months, were enrolled. All subjects had no history of sleep disorders. Actigraphy was used to study sleep patterns during a seven-day period. Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI). Twenty healthy subjects served as controls.

Results: Our results showed statistically significant differences between some actigraphic patterns in MS patients treated with dimethylfumarate and healthy subjects, but the values for patients were still within normal limits. PSQI score was higher in MS patients compared to controls.

Conclusion: Our findings suggest that dimethylfumarate, an oral DMT with a favourable benefit-risk profile, does not strongly alter sleep patterns in MS patients with low to mild disability and with no history of sleep disorders. Actigraphy is a simple diagnostic tool, able to support an objective measure of sleep parameters. The simplicity of application may allow considering its use for a screening of sleep disorders in MS patients.

Keywords: Sleep, multiple sclerosis, dimethylfumarate, actigraphy, disease-modifying treatment, sleep disorders.

[1]
World Health Organization. Atlas multiple sclerosis resources in the world 2008. Geneva: WHO Press 2008.
[2]
Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: Clinical aspects. Curr Opin Neurol 2018; 31(6): 752-9.
[http://dx.doi.org/10.1097/WCO.0000000000000622] [PMID: 30300239]
[3]
Veauthier C, Paul F. Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Med 2014; 15(1): 5-14.
[http://dx.doi.org/10.1016/j.sleep.2013.08.791] [PMID: 24360534]
[4]
Braley TJ, Boudreau EA. Sleep disorders in multiple sclerosis. Curr Neurol Neurosci Rep 2016; 16(5): 50.
[http://dx.doi.org/10.1007/s11910-016-0649-2] [PMID: 27068547]
[5]
Buratti L, Iacobucci DE, Viticchi G, et al. Sleep quality can influence the outcome of patients with multiple sclerosis. Sleep Med 2019; 58: 56-60.
[http://dx.doi.org/10.1016/j.sleep.2019.02.020] [PMID: 31129524]
[6]
van Wijngaarden P, Franklin RJM. Ageing stem and progenitor cells: Implications for rejuvenation of the central nervous system. Development 2013; 140(12): 2562-75.
[http://dx.doi.org/10.1242/dev.092262] [PMID: 23715549]
[7]
Franklin RJM, Ffrench-Constant C. Remyelination in the CNS: From biology to therapy. Nat Rev Neurosci 2008; 9(11): 839-55.
[http://dx.doi.org/10.1038/nrn2480] [PMID: 18931697]
[8]
Bellesi M, Pfister-Genskow M, Maret S, Keles S, Tononi G, Cirelli C. Effects of sleep and wake on oligodendrocytes and their precursors. J Neurosci 2013; 33(36): 14288-300.
[http://dx.doi.org/10.1523/JNEUROSCI.5102-12.2013] [PMID: 24005282]
[9]
Lanza G, Ferri R, Bella R, Ferini-Strambi L. The impact of drugs for multiple sclerosis on sleep. Mult Scler 2017; 23(1): 5-13.
[http://dx.doi.org/10.1177/1352458516664034] [PMID: 27503906]
[10]
Rocchi C, Pulcini A, Vesprini C, et al. Sleep in multiple sclerosis patients treated with interferon beta: An actigraphic study. Neurol Res 2020; 42(9): 744-8.
[http://dx.doi.org/10.1080/01616412.2020.1773629] [PMID: 32520662]
[11]
Montes Diaz G, Hupperts R, Fraussen J, Somers V. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies. Autoimmun Rev 2018; 17(12): 1240-50.
[http://dx.doi.org/10.1016/j.autrev.2018.07.001] [PMID: 30316988]
[12]
Lanzillo R, Moccia M, Palladino R, et al. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: A real life multicentre study. Mult Scler Relat Disord 2020; 38: 101871.
[http://dx.doi.org/10.1016/j.msard.2019.101871] [PMID: 31786463]
[13]
Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol 2014; 14(1): 58.
[http://dx.doi.org/10.1186/1471-2377-14-58] [PMID: 24666846]
[14]
Besedovsky L, Lange T, Haack M. The sleep-immune crosstalk in health and disease. Physiol Rev 2019; 99(3): 1325-80.
[http://dx.doi.org/10.1152/physrev.00010.2018] [PMID: 30920354]
[15]
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46(10): 1121-3.
[http://dx.doi.org/10.1001/archneur.1989.00520460115022] [PMID: 2803071]
[16]
Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 1989; 28(2): 193-213.
[http://dx.doi.org/10.1016/0165-1781(89)90047-4] [PMID: 2748771]
[17]
Grandner MA, Kripke DF, Yoon I-Y, Youngstedt SD. Criterion validity of the Pittsburgh Sleep Quality Index: Investigation in a non-clinical sample. Sleep Biol Rhythms 2006; 4(2): 129-39.
[http://dx.doi.org/10.1111/j.1479-8425.2006.00207.x] [PMID: 22822303]
[18]
Backhaus J, Junghanns K, Broocks A, Riemann D, Hohagen F. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res 2002; 53(3): 737-40.
[http://dx.doi.org/10.1016/S0022-3999(02)00330-6] [PMID: 12217446]
[19]
Brass SD, Li CS, Auerbach S. The underdiagnosis of sleep disorders in patients with multiple sclerosis. J Clin Sleep Med 2014; 10(9): 1025-31.
[http://dx.doi.org/10.5664/jcsm.4044] [PMID: 25142763]
[20]
Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: Developing normative sleep values across the human lifespan. Sleep 2004; 27(7): 1255-73.
[http://dx.doi.org/10.1093/sleep/27.7.1255] [PMID: 15586779]
[21]
Hertenstein E, Gabryelska A, Spiegelhalder K, et al. Reference data for polysomnography-measured and subjective sleep in healthy adults. J Clin Sleep Med 2018; 14(4): 523-32.
[http://dx.doi.org/10.5664/jcsm.7036] [PMID: 29609718]
[22]
Bøe Lunde HM, Aae TF, Indrevåg W, et al. Poor sleep in patients with multiple sclerosis. PLoS One 2012; 7(11): e49996.
[http://dx.doi.org/10.1371/journal.pone.0049996] [PMID: 23166808]
[23]
Braley TJ, Huber AK, Segal BM, et al. A randomized, subject and rater-blinded, placebo-controlled trial of dimethyl fumarate for obstructive sleep apnea. Sleep 2018; 41(8): 109.
[http://dx.doi.org/10.1093/sleep/zsy109] [PMID: 29800466]
[24]
Irwin MR. Sleep and inflammation: Partners in sickness and in health. Nat Rev Immunol 2019; 19(11): 702-15.
[http://dx.doi.org/10.1038/s41577-019-0190-z] [PMID: 31289370]